WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced a $200 million non-dilutive royalty transaction with funds managed by TPG Special Situations Partners (“TSSP”).
Help employers find you! Check out all the jobs and post your resume.
